During the past decade, University of California, San Francisco-Fresno conducted 39 clinical trials. In the 10-year time frame, 39 clinical trials started and 28 clinical trials were completed, i.e. on average, 71.8% percent of trials that started reached the finish line to date. In the past 5 years, 18 clinical trials started and 21 clinical trials were completed. i.e. 116.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "University of California, San Francisco-Fresno" #1 sponsor was "United Therapeutics" with 9 trials, followed by "University of California, San Francisco" with 7 trials sponsored, "Massachusetts General Hospital" with 6 trials sponsored, "National Heart, Lung, and Blood Institute (NHLBI)" with 5 trials sponsored and "Actelion" with 5 trials sponsored. Other sponsors include 37 different institutions and companies that sponsored additional 42 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "University of California, San Francisco-Fresno" #1 collaborator was "National Heart, Lung, and Blood Institute (NHLBI)" with 4 trials as a collaborator, "National Institute of Neurological Disorders and Stroke (NINDS)" with 3 trials as a collaborator, "United States Department of Defense" with 3 trials as a collaborator, "Patient-Centered Outcomes Research Institute" with 2 trials as a collaborator and "University of Alabama at Birmingham" with 2 trials as a collaborator. Other collaborators include 11 different institutions and companies that were collaborators in the rest 21 trials.

According to Clinical.Site data, the most researched conditions in "University of California, San Francisco-Fresno" are "Pulmonary Arterial Hypertension" (9 trials), "Pulmonary Hypertension" (6 trials), "Acute Respiratory Distress Syndrome" (4 trials), "Amyotrophic Lateral Sclerosis" (3 trials) and "Respiratory Distress Syndrome, Adult" (3 trials). Many other conditions were trialed in "University of California, San Francisco-Fresno" in a lesser frequency.

Most popular intervention types in "University of California, San Francisco-Fresno" are "Drug" (51 trials), "Other" (12 trials), "Device" (5 trials), "Behavioral" (4 trials) and "Biological" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (26 trials), "placebo" (3 trials), "Dexpramipexole" (2 trials), "Full Feeding" (2 trials) and "Inhaled Treprostinil" (2 trials). Other intervention names were less common.

The vast majority of trials in "University of California, San Francisco-Fresno" are 70 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "University of California, San Francisco-Fresno". undefined are not yet recruiting, 7 are recruiting, 7 are Active, not recruiting, and 3 are Enrolling by invitation. In total, there were 36 completed trials in University of California, San Francisco-Fresno, undefined suspended trials, and 14 terminated clinical trials to date.

Out of the total trials that were conducted in University of California, San Francisco-Fresno, 1 "Phase 1" clinical trials were conducted, 14 "Phase 2" clinical trials and 40 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 7 trials that are defined as “Not Applicable".